CBS 2019
CBSMD教育中心
中 文

Scientific Library

Abstract

Recommended Article

Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry 5-Year Outcomes After TAVR With Balloon-Expandable Versus Self-Expanding Valves: Results From the CHOICE Randomized Clinical Trial Selection of stenting approach for coronary bifurcation lesions Diagnostic Performance of the Instantaneous Wave-Free Ratio: Comparison With Fractional Flow Reserve Clinical Relevance of Functionally Insignificant Moderate Coronary Artery Stenosis Assessed by 3-Vessel Fractional Flow Reserve Measurement Incidence of Adverse Events at 3 Months Versus at 12 Months After Dual Antiplatelet Therapy Cessation in Patients Treated With Thin Stents With Unprotected Left Main or Coronary Bifurcations Pulmonary hypertension related to congenital heart disease: a call for action

Clinical Trial2014 Jan 21;129(3):304-12.

JOURNAL:Circulation. Article Link

Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial.

Lee CW, Ahn JM, Park SJ et al. Keywords: dAPT duration; coronary artery disease; DES; platelet aggregation; inhibitors; stents; thrombosis

FULL TEXT PDF